PPMD recently held a community webinar to discuss the recently shared Phase 3 topline results of the EMBARK study (SRP-9001-301). Crystal Proud, MD, provided an overview of the study topline results, highlighting that EMBARK achieved statistical significance on all pre-specified key secondary endpoints. Dr. Proud noted that while the primary endpoint was not met in this initial 52 week data cut, the data from EMBARK demonstrates substantial evidence of safety and effectiveness of SRP-9001, including impact on key secondary endpoints that are known to be predictors of disease progression.
Siobhan Fitzgerald, Executive Director of Patient Affairs at Sarepta Therapeutics, also joined the webinar to answer frequently asked questions related to plans moving forward.